Cardiovascular disease and diabetes in HIV ‐positive and HIV‐negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study
ConclusionsHIV ‐positive GBM more commonly reported heart disease and thrombosis compared with their HIV‐negative peers. These results further highlight the need to understand the impact of HIV on age‐related comorbidities in GBM, to guide optimal screening and treatment strategies to reduce the risk of thes e comorbidities among the HIV‐positive population. (Source: HIV Medicine)
Source: HIV Medicine - November 26, 2018 Category: Infectious Diseases Authors: R Puhr,
K Petoumenos,
R Huang,
DJ Templeton,
I Woolley,
M Bloch,
D Russell,
MG Law,
DA Cooper Tags: Original Research Source Type: research
Lost but not forgotten: A population ‐based study of mortality and care trajectories among people living with HIV who are lost to follow‐up in Ontario, Canada
ConclusionsMortality risk and use of health care resources were lower among active cohort participants. Our findings may inform health outcome estimates based on volunteer cohorts, as well as quantitative bias adjustment to correct for such biases. (Source: HIV Medicine)
Source: HIV Medicine - November 26, 2018 Category: Infectious Diseases Authors: CE Kendall,
J Raboud,
J Donelle,
M Loutfy,
SB Rourke,
A Kroch,
C Liddy,
R Rosenes,
Ontario HIV Treatment Network (OHTN) Cohort Study Team,
AN Burchell,
Jeffrey Cohen,
Don Kilby,
Fred Crouzat,
Nisha Andany,
Nicole Mittmann,
Irving Salit,
Mi Tags: Original Research Source Type: research
Hepatic and renal toxicity and associated factors among HIV ‐infected children on antiretroviral therapy: a prospective cohort study
ConclusionsA high prevalence of liver enzyme and renal function abnormalities was observed at enrolment. Decreasing liver enzyme levels during follow ‐up are possibly reassuring, while the progressive reduction in GFR and the increase in BUN are worrisome and require further study. (Source: HIV Medicine)
Source: HIV Medicine - November 26, 2018 Category: Infectious Diseases Authors: BT Tadesse,
BA Foster,
A Kabeta,
F Ayalew,
G H/Meskel,
D Jerene,
E Makonnen,
E Aklillu Tags: Original Research Source Type: research
Evolution of major non ‐HIV‐related comorbidities in HIV‐infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014
ConclusionsThe burden of NCDs in our PLWHIV population markedly worsened over a 10 ‐year time‐span, which is likely to be a result of the effects of both ageing and HIV infection as well as their interaction. Special attention must be given to the management and prevention of NCDs. (Source: HIV Medicine)
Source: HIV Medicine - November 21, 2018 Category: Infectious Diseases Authors: A d'Arminio Monforte,
H Diaz ‐Cuervo,
A De Luca,
F Maggiolo,
A Cingolani,
S Bonora,
A Castagna,
E Girardi,
A Antinori,
S Lo Caputo,
G Guaraldi,
A Cozzi‐Lepri, on behalf of
the ICONA Foundation Study Group,
F Castelli,
R. Cauda,
G. Perr Tags: Original Research Source Type: research
Prevalence and determinants of resistance mutations in HIV ‐1‐infected patients exposed to integrase inhibitors in a large Italian cohort
ConclusionsThe results support integrase resistance testing in INSTI ‐experienced patients. Emergence of INSTI resistance is facilitated by the reduced genetic barrier of the regimen as a consequence of resistance to companion drugs. However, INSTI resistance may become undetectable by standard population sequencing upon INSTI discontinuation. (Source: HIV Medicine)
Source: HIV Medicine - November 21, 2018 Category: Infectious Diseases Authors: S Modica,
B Rossetti,
F Lombardi,
F Lagi,
M Maffeo,
R D'Autilia,
M Pecorari,
I Vicenti,
B Bruzzone,
G Magnani,
S Paolucci,
D Francisci,
G Penco,
D Sacchini,
M Zazzi,
A De Luca,
A Di Biagio Tags: Original Research Source Type: research
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV ‐infected patients in clinical practice: results from a multicentre, observational study
ConclusionsSwitching to dolutegravir + emtricitabine/TDF was associated with similar efficacy and tolerability to switching to elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed patients in clinical practice, although reasons for discontinuation showed differences between regimens. These results should be interpreted with caution, as this is a nonrandomized comparison. (Source: HIV Medicine)
Source: HIV Medicine - November 20, 2018 Category: Infectious Diseases Authors: G Baldin,
A Ciccullo,
A Capetti,
S Rusconi,
G Sterrantino,
MV Cossu,
A Giacomelli,
F Lagi,
A Latini,
P Bagella,
A De Luca,
S Di Giambenedetto,
G Madeddu Tags: Short Communication Source Type: research
Inequalities in HIV testing uptake and needs among men who have sex with men living in Ireland: findings from an internet survey
ConclusionsHIV prevention and testing programmes for MSM should be targeted towards younger men, those living outside Dublin and those with lower levels of education. We recommend increased promotion and availability of free HIV testing services in a range of clinical and nonclinical settings (including self ‐sampling and home testing). (Source: HIV Medicine)
Source: HIV Medicine - November 20, 2018 Category: Infectious Diseases Authors: K O'Donnell,
M Fitzgerald,
M Quinlan,
F Hickson,
P Keogh,
AJ Schmidt,
D McCartney,
P Barrett,
S O'Dea,
D Igoe Tags: Original Research Source Type: research
Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999 –2013)
ConclusionsLate presentation is common in Ontario, as it is in other high ‐income countries. Our findings suggest that efforts to reduce late presentation should focus on facilitating earlier diagnosis for the populations identified in this analysis. (Source: HIV Medicine)
Source: HIV Medicine - November 14, 2018 Category: Infectious Diseases Authors: J Wilton,
L Light,
S Gardner,
B Rachlis,
T Conway,
C Cooper,
P Cupido,
CE Kendall,
M Loutfy,
F McGee,
J Murray,
J Lush,
A Rachlis,
W Wobeser,
J Bacon,
AE Kroch,
M Gilbert,
SB Rourke,
AN Burchell, on behalf of
Ontario HIV Treatment Netwo Tags: Original Research Source Type: research
Acute kidney injury in HIV ‐infected patients: a critical review
Acute kidney injury (AKI) is characterized by a rapid decline of renal function associated with worse outcomes. The purpose of the authors is to perform a critical review of the incidence, risk factors, pathogenesis and outcome of AKI in HIV ‐infected patients. Human immunodeficiency virus (HIV)‐infected patients have an increased risk of developing AKI, to which contribute both HIV‐dependent and HIV‐independent factors as well as the nephrotoxicity of drugs used. The increased risk of AKI in HIV‐infected patients and its nega tive impact on prognosis highlights the need for identification of patients at risk, cr...
Source: HIV Medicine - November 8, 2018 Category: Infectious Diseases Authors: J Gameiro,
J Agapito Fonseca,
S Jorge,
JA Lopes Tags: Reviews in Antiretroviral Research Source Type: research
Risk of neurosyphilis in HIV ‐infected persons with syphilis lacking signs or symptoms of central nervous system infection
ConclusionsThis large number of potentially unnecessary LPs, along with heterogeneity of presentation, and the never ‐nil risk of asymptomatic neurosyphilis should be incorporated into clinical decision‐making. The majority of PLWH presenting with a serological diagnosis of syphilis, but no neurological signs or symptoms, do not necessarily require an LP for an evaluation of asymptomatic neurosyphilis. (Source: HIV Medicine)
Source: HIV Medicine - November 7, 2018 Category: Infectious Diseases Authors: L Rotman,
X Luo,
A Thompson,
ME Mackesy ‐Amiti,
LR Young,
JD Young Tags: Original Research Source Type: research
Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM)
HIV Medicine, EarlyView. (Source: HIV Medicine)
Source: HIV Medicine - October 26, 2018 Category: Infectious Diseases Authors: F Li égeois,
S Eymard‐Duvernay,
S Boyer,
G Maradan,
C Kouanfack,
J Domyeum,
V Boyer,
E Mpoudi‐Ngolé,
B Spire,
E Delaporte,
L Vidal,
C Kuaban,
C Laurent, for
the EVOLCAM study group,
A Ambani,
O Ndalle,
P Momo,
C Tong,
L March,
M Source Type: research
Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV ‐Infected Individuals
HIV Medicine, EarlyView. (Source: HIV Medicine)
Source: HIV Medicine - October 26, 2018 Category: Infectious Diseases Authors: A Balasko,
Y Keynan Source Type: research
Issue Information
HIV Medicine,Volume 19, Issue 10, Page 1-2, November 2018. (Source: HIV Medicine)
Source: HIV Medicine - October 19, 2018 Category: Infectious Diseases Source Type: research
A note of thanks to referees for Volume 19, 2018
HIV Medicine,Volume 19, Issue 10, Page 756-758, November 2018. (Source: HIV Medicine)
Source: HIV Medicine - October 19, 2018 Category: Infectious Diseases Source Type: research
Management of Renal Disease: utility of a joint HIV ‐renal clinic
HIV Medicine, EarlyView. (Source: HIV Medicine)
Source: HIV Medicine - October 15, 2018 Category: Infectious Diseases Authors: D Williams,
J Scott,
D Richardson,
E Kingdon Source Type: research
